Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,036.90down ₹31.90 (2.98%)BSE ₹1,037.80
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,068.80.
2 Nov: open ₹1,067.30, high ₹1,067.30, low ₹1,013.90
52-week range of traded prices to 2 Nov 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,557 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.48%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,07,98637.7% delivered
Strides Pharma Science board and management
43 filed, newest first.
Oct 2026
May 2026
18 May · Management
18 May · Management
Dec 2025
3 Dec · Management
Jul 2025
28 Jul · Management
May 2025
Jan 2025
30 Jan · Management
Nov 2024
Oct 2024
24 Oct · Management
Aug 2024
28 Aug · Management
Jul 2024
30 Jul · Management
May 2024
22 May · Management
22 May · Management
Jan 2024
Oct 2023
30 Oct · Management
30 Oct · Management
Sep 2023
1 Sep · Management
Nov 2022
Mar 2022
Jan 2020
8 Jan · Management
Mar 2018
Sep 2017
15 Sep · Management
15 Sep · Management
May 2017
18 May · Management
Feb 2016
Nov 2015
Dec 2014
Jul 2014
May 2014
26 May · Management
As per the provisions of Section 283(1)(g) of the Companies Act, 1956, Mr K.R Ravishankar, Non-Executive Director of the Company, ceases to be a Director of the Company w.e.f February 07, 2014.
Feb 2014
Aug 2013
Jul 2012
May 2012
28 May · Management
Mr. Venkat S. Iyer, CEO of Agila Specialties and Executive Director of the Company steps down as Executive Director of Strides w.e.f. May 25, 2012 to fully focus on the global injectable Agila business.
Apr 2012
27 Apr · Management
Mr. Virtanes Saatci a non-executive Director on the Board of the Company has resigned with effect from April 26, 2012.
Oct 2010
15 Oct · Management
Dr. Ronald Ling, a non executive director on the Board of the Company has resigned from the company with effect from October 14, 2010.
Sep 2010
1 Sep · Management
Export-Import Bank of India, Mumbai has nominated Mr. Mukul Sarkar as Nominee Director in place of Mr. John Mathew on the Board of our Company with effect from August 31, 2010
Jul 2009
10 Jul · Management
Export-Import Bank of India, Mumbai has nominated Mr. John Mathew as Nominee Director in place of Mr. D G Prasad on the Board of the Company with effect from July 01, 2009.
Feb 2009
27 Feb · Management
Auditor's report in respect of the audited financial results for the quarter ended December 31,2008.A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
12 Nov · Management
Mr. Elcemar Almeida has resigned from the Board of Directors of the Company
Mar 2008
7 Mar · Management
Auditor's report for the financial year ended December 31, 2007. A Copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
10 Apr · Management
Dr. Francis J. Pinto has resigned from the Board of Directors of the Company